How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

This study aimed to: (1) estimate the disease burden of herpes zoster (HZ) and (2) assess the potential public health impact of introducing adjuvanted recombinant zoster vaccine (RZV) compared with no vaccination in adults aged ≥50 years in Argentina, Brazil, Mexico, Chile, and Colombia using the ZO...

Full description

Bibliographic Details
Main Authors: Ru Han, Jorge A. Gomez, Bruna de Veras, Thatiana Pinto, Adriana Guzman-Holst, Javier Nieto, Désirée A. M. van Oorschot
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster
post-herpetic neuralgia, recombinant zoster vaccine
public health impact
latin america
argentina
brazil
mexico
chile
colombia
Online Access:http://dx.doi.org/10.1080/21645515.2022.2164144

Internet

http://dx.doi.org/10.1080/21645515.2022.2164144

Similar Items